Active Biotech AB Interim Report January - March 2012

LUND, SWEDEN--(Marketwire - April 26, 2012) -

 * Laquinimod - submission of application for regulatory approval in the EU planned for second half of 2012 - Phase III data presented at the Annual Meeting of the American Academy of Neurology (AAN) * TASQ - a Phase I investigator-sponsored clinical trial is under way - enrolment of patients to Phase III study proceeding according to schedule * ANYARA - Phase III trial continuing according to plan * 57-57 - a clinical trial in systemic sclerosis/scleroderma in progress * ISI - project is proceeding as planned * Net sales SEK 2.6 M (2.7) * Operating loss SEK 100.7 M (loss: 70.9) * Net loss SEK 99.0 M (loss: 69.3 ) * Loss per share for the period was SEK 1.44 (loss: 1.02) 

This report is also available at www.activebiotech.com

Active Biotech AB Interim report January - March 2012: http://hugin.info/1002/R/1605995/508858.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE [HUG#1605995]